Interestingly, the mitochondrial serine and glycine catabolic enzymes SHMT2 and MTHFD2 showed robust elevations in low glucose versus high glucose treatment in the cancer cells and in BEC on the mRNA levels, but in the latter the increase only occurred in combination with low serine/glycine availability (Fig. 2B). The gene discussed is MTHFD2; the disease is cancer.